Sunshine for heart failure
Profile of Sunshine Heart's C-Pulse heart pump, its US trials and trial funding plans, recalling the failure of fellow Australian device maker Ventracor during the global financial crisis.
Company
Every investor coverage indicates participated in a round Ventracor raised.
Companies Ventracor acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Victor Windeyer | Program Manager (former) | GBS Ventures (30 May 2007), GBS Ventures (5 Dec 2005) |
Stories naming Ventracor. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of Sunshine Heart's C-Pulse heart pump, its US trials and trial funding plans, recalling the failure of fellow Australian device maker Ventracor during the global financial crisis.
Sunshine Heart's Sydney subsidiary has named Victor Windeyer general manager while he remains chief operating officer of the American-listed parent, overseeing Australian operations ahead of a planned United States clinical trial filing.
Sunshine Heart appoints Victor Windeyer as chief operating officer to lead its Australian operations and C-Pulse clinical trials from Sydney; the company also cites a secured grant and ethics approvals at two Melbourne hospitals.
Also GBS Ventures
Medtech company Sunshine Heart has brought in Ruth Flynn as its first clinical affairs manager, to drive C-Pulse heart assist device trials across Australia and New Zealand from its Sydney head office.